Update on the impact of omega 3 fatty acids on inflammation, insulin resistance and sarcopenia: A review

International Journal of Molecular Sciences

Volumn 19, Issue 1, 2018, Pages

  Stella, Alex Buoite ^a   Cappellari, Gianluca Gortan ^a   Barazzoni, Rocco ^a   Zanetti, Michela ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Aging; Chronic kidney disease; Inflammation; Insulin resistance; Omega 3 fatty acids; Sarcopenia

Indexed keywords

ADIPONECTIN; C PEPTIDE; CELL ADHESION MOLECULE; DOCOSAHEXAENOIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; ICOSAPENTAENOIC ACID; LEPTIN; LOW DENSITY LIPOPROTEIN; OMEGA 3 FATTY ACID; PIOGLITAZONE; RETINOL BINDING PROTEIN; ANTIINFLAMMATORY AGENT;

CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET SUPPLEMENTATION; END STAGE RENAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMODIALYSIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; INSULIN RESISTANCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; METABOLIC SYNDROME X; MUSCLE MASS; MUSCLE WEAKNESS; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; REVIEW; SARCOPENIA; LIPID METABOLISM; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTI-INFLAMMATORY AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SARCOPENIA;

EID: 85040575099     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19010218     Document Type: Review

References (61)

1. Sinclair, A.J.; Abdelhafiz, A.H.; Rodriguez-Manas, L. Frailty and sarcopenia—Newly emerging and high impact complications of diabetes. J. Diabetes Complicat. 2017, 31, 1465-1473. [CrossRef] [PubMed]
2. Chow, L.S.; Nair, K.S. Sarcopenia of male aging. Endocrinol. Metab. Clin. N. Am. 2005, 34, 833-852. [CrossRef] [PubMed]
3. Johns, N.; Stephens, N.A.; Fearon, K.C.H. Muscle wasting in cancer. Int. J. Biochem. Cell Biol. 2013, 45, 2215-2229. [CrossRef] [PubMed]
4. Cohen, S.; Nathan, J.A.; Goldberg, A.L. Muscle wasting in disease: Molecular mechanisms and promising therapies. Nat. Rev. Drug Discov. 2015, 14, 58-74. [CrossRef] [PubMed]
5. Jo, E.; Lee, S.-R.; Park, B.-S.; Kim, J.-S. Potential mechanisms underlying the role of chronic inflammation in age-related muscle wasting. Aging Clin. Exp. Res. 2012, 24, 412-422. [CrossRef] [PubMed]
6. Wu, H.; Ballantyne, C.M. Skeletal muscle inflammation and insulin resistance in obesity. J. Clin. Investig. 2017, 127, 43-54. [CrossRef] [PubMed]
7. Jackson, M.J. Reactive oxygen species in sarcopenia: Should we focus on excess oxidative damage or defective redox signalling? Mol. Asp. Med. 2016, 50, 33-40. [CrossRef] [PubMed]
8. Oh, S.-L.; Lee, S.-R.; Kim, J.-S. Effects of conjugated linoleic acid/n-3 and resistance training on muscle quality and expression of atrophy-related ubiquitin ligases in middle-aged mice with high-fat dietinduced obesity. J. Exerc. Nutr. Biochem. 2017, 21, 11-18. [CrossRef] [PubMed]
9. Smith, G.I.; Atherton, P.; Reeds, D.N.; Mohammed, B.S.; Rankin, D.; Rennie, M.J.; Mittendorfer, B. Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin. Sci. 2011, 121, 267-278. [CrossRef] [PubMed]
10. Di Girolamo, F.G.; Situlin, R.; Mazzucco, S.; Valentini, R.; Toigo, G.; Biolo, G. Omega-3 fatty acids and protein metabolism: Enhancement of anabolic interventions for sarcopenia. Curr. Opin. Clin. Nutr. Metab. Care 2014, 17, 145-150. [CrossRef] [PubMed]
11. Farias, J.G.; Molina, V.M.; Carrasco, R.A.; Zepeda, A.B.; Figueroa, E.; Letelier, P.; Castillo, R.L. Antioxidant Therapeutic Strategies for Cardiovascular Conditions Associated with Oxidative Stress. Nutrients 2017, 9. [CrossRef] [PubMed]
12. Calder, P.C. Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem. Soc. Trans. 2017, 45, 1105-1115. [CrossRef] [PubMed]
13. Lucero, D.; Olano, C.; Bursztyn, M.; Morales, C.; Stranges, A.; Friedman, S.; Macri, E.V.; Schreier, L.; Zago, V. Supplementation with n-3, n-6, n-9 fatty acids in an insulin-resistance animal model: Does it improve VLDL quality? Food Funct. 2017, 8, 2053-2061. [CrossRef] [PubMed]
14. Asztalos, I.B.; Gleason, J.A.; Sever, S.; Gedik, R.; Asztalos, B.F.; Horvath, K.V.; Dansinger, M.L.; Lamon-Fava, S.; Schaefer, E.J. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: A randomized clinical trial. Metabolism 2016, 65, 1636-1645. [CrossRef] [PubMed]
15. Polus, A.; Zapala, B.; Razny, U.; Gielicz, A.; Kiec-Wilk, B.; Malczewska-Malec, M.; Sanak, M.; Childs, C.E.; Calder, P.C.; Dembinska-Kiec, A. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochim. Biophys. Acta 2016, 1861, 1746-1755. [CrossRef] [PubMed]
16. Logan, S.L.; Spriet, L.L. Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females. PLoS ONE 2015, 10, e0144828. [CrossRef] [PubMed]
17. Smith, G.I.; Julliand, S.; Reeds, D.N.; Sinacore, D.R.; Klein, S.; Mittendorfer, B. Fish oil-derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am. J. Clin. Nutr. 2015, 102, 115-122. [CrossRef] [PubMed]
18. Alves Luzia, L.; Mendes Aldrighi, J.; Teixeira Damasceno, N.R.; Rodrigues Sampaio, G.; Aparecida Manolio Soares, R.; Tande Silva, I.; De Queiroz Mello, A.P.; Ferreira Carioca, A.A.; Ferraz da Silva Torres, E.A. Fish oil and vitamin e change lipid profiles and anti-LDL-antibodies in two different ethnic groups of women transitioning through menopause. Nutr. Hosp. 2015, 32, 165-174. [CrossRef] [PubMed]
19. Moeinzadeh, F.; Shahidi, S.; Mortazavi, M.; Dolatkhah, S.; Kajbaf, M.; Haghjooy Javanmard, S.; Moghtaderi, A. Effects of Omega-3 Fatty Acid Supplementation on Serum Biomarkers, Inflammatory Agents, and Quality of Life of Patients on Hemodialysis. Iran. J. Kidney Dis. 2016, 10, 381-387. [PubMed]
20. Kajbaf, M.H.; Khorvash, F.; Mortazavi, M.; Shahidi, S.; Moeinzadeh, F.; Farajzadegan, Z.; Tirani, S.A. Does Omega-3 supplementation decrease carotid intima-media thickening in hemodialysis patients? J. Res. Pharm. Pract. 2016, 5, 252-256. [CrossRef] [PubMed]
21. Gharekhani, A.; Dashti-Khavidaki, S.; Lessan-Pezeshki, M.; Khatami, M.-R. Potential Effects of Omega-3 Fatty Acids on Insulin Resistance and Lipid Profile in Maintenance Hemodialysis Patients: A Randomized Placebo-Controlled Trial. Iran. J. Kidney Dis. 2016, 10, 310-318. [PubMed]
22. Deger, S.M.; Hung, A.M.; Ellis, C.D.; Booker, C.; Bian, A.; Chen, G.; Abumrad, N.N.; Ikizler, T.A. High Dose Omega-3 Fatty Acid Administration and Skeletal Muscle Protein Turnover in Maintenance Hemodialysis Patients. Clin. J. Am. Soc. Nephrol. 2016, 11, 1227-1235. [CrossRef] [PubMed]
23. Omrani, H.R.; Pasdar, Y.; Raisi, D.; Najafi, F.; Esfandiari, A. The effect of omega-3 on serum lipid profile in hemodialysis patients. J. Ren. Inj. Prev. 2015, 4, 68-72. [CrossRef] [PubMed]
24. Naini, A.E.; Asiabi, R.E.K.; Keivandarian, N.; Moeinzadeh, F. Effect of omega-3 supplementation on inflammatory parameters in patients on chronic ambulatory peritoneal dialysis. Adv. Biomed. Res. 2015, 4, 167. [CrossRef] [PubMed]
25. Taheri, S.; Keyvandarian, N.; Moeinzadeh, F.; Mortazavi, M.; Naini, A.E. The effect of omega-3 fatty acid supplementation on oxidative stress in continuous ambulatory peritoneal dialysis patients. Adv. Biomed. Res. 2014, 3, 143. [CrossRef] [PubMed]
26. Naini, A.E.; Keyvandarian, N.; Mortazavi, M.; Taheri, S.; Hosseini, S.M. Effect of Omega-3 fatty acids on blood pressure and serum lipids in continuous ambulatory peritoneal dialysis patients. J. Res. Pharm. Pract. 2015, 4, 135-141. [CrossRef] [PubMed]
27. Sawada, T.; Tsubata, H.; Hashimoto, N.; Takabe, M.; Miyata, T.; Aoki, K.; Yamashita, S.; Oishi, S.; Osue, T.; Yokoi, K.; et al. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. A. Cardiovasc. Diabetol. 2016, 15, 121. [CrossRef] [PubMed]
28. Clark, L.F.; Thivierge, M.C.; Kidd, C.A.; McGeoch, S.C.; Abraham, P.; Pearson, D.W.M.; Horgan, G.W.; Holtrop, G.; Thies, F.; Lobley, G.E. Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: A parallel randomised controlled trial. Br. J. Nutr. 2016, 115, 75-86. [CrossRef] [PubMed]
29. Poreba, M.; Mostowik, M.; Siniarski, A.; Golebiowska-Wiatrak, R.; Malinowski, K.P.; Haberka, M.; Konduracka, E.; Nessler, J.; Undas, A.; Gajos, G. Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. Cardiovasc. Diabetol. 2017, 16, 50. [CrossRef] [PubMed]
30. Toorang, F.; Djazayery, A.; Djalali, M. Effects of Omega-3 Fatty Acids Supplement on Antioxidant Enzymes Activity in Type 2 Diabetic Patients. Iran. J. Public Health 2016, 45, 340-345. [PubMed]
31. Farahbakhsh-Farsi, P.; Djazayery, A.; Eshraghian, M.R.; Koohdani, F.; Zarei, M.; Javanbakht, M.H.; Derakhshanian, H.; Djalali, M. Effect of Omega-3 Supplementation on Lipocalin 2 and Retinol-Binding Protein 4 in Type 2 Diabetic Patients. Iran. J. Public Health 2016, 45, 179-185. [PubMed]
32. Veleba, J.; Kopecky, J.J.; Janovska, P.; Kuda, O.; Horakova, O.; Malinska, H.; Kazdova, L.; Oliyarnyk, O.; Skop, V.; Trnovska, J.; et al. Combined intervention with pioglitazone and n-3 fatty acids in metformin-treated type 2 diabetic patients: Improvement of lipid metabolism. Nutr. Metab. 2015, 12, 52. [CrossRef] [PubMed]
33. Dasarathy, S.; Dasarathy, J.; Khiyami, A.; Yerian, L.; Hawkins, C.; Sargent, R.; McCullough, A.J. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2015, 49, 137-144. [CrossRef] [PubMed]
34. Lee, T.C.; Ivester, P.; Hester, A.G.; Sergeant, S.; Case, L.D.; Morgan, T.; Kouba, E.O.; Chilton, F.H. The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population. Lipids Health Dis. 2014, 13, 196. [CrossRef] [PubMed]
35. Venturini, D.; Simao, A.N.C.; Urbano, M.R.; Dichi, I. Effects of extra virgin olive oil and fish oil on lipid profile and oxidative stress in patients with metabolic syndrome. Nutrition 2015, 31, 834-840. [CrossRef] [PubMed]
36. Simao, A.N.C.; Lozovoy, M.A.B.; Dichi, I. Effect of soy product kinako and fish oil on serum lipids and glucose metabolism in women with metabolic syndrome. Nutrition 2014, 30, 112-115. [CrossRef] [PubMed]
37. Muldoon, M.F.; Laderian, B.; Kuan, D.C.H.; Sereika, S.M.; Marsland, A.L.; Manuck, S.B. Fish oil supplementation does not lower C-reactive protein or interleukin-6 levels in healthy adults. J. Intern. Med. 2016, 279, 98-109. [CrossRef] [PubMed]
38. Flock, M.R.; Skulas-Ray, A.C.; Harris, W.S.; Gaugler, T.L.; Fleming, J.A.; Kris-Etherton, P.M. Effects of supplemental long-chain omega-3 fatty acids and erythrocyte membrane fatty acid content on circulating inflammatory markers in a randomized controlled trial of healthy adults. Prostaglandins Leukot. Essent. Fatty Acids 2014, 91, 161-168. [CrossRef] [PubMed]
39. Bo, Y.; Zhang, X.; Wang, Y.; You, J.; Cui, H.; Zhu, Y.; Pang, W.; Liu, W.; Jiang, Y.; Lu, Q. The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial. Nutrients 2017, 9. [CrossRef] [PubMed]
40. Gharekhani, A.; Khatami, M.-R.; Dashti-Khavidaki, S.; Razeghi, E.; Noorbala, A.-A.; Hashemi-Nazari, S.-S.; Mansournia, M.-A. The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: A randomized, placebo-controlled clinical trial. Eur. J. Clin. Pharmacol. 2014, 70, 655-665. [CrossRef] [PubMed]
41. Gharekhani, A.; Khatami, M.-R.; Dashti-Khavidaki, S.; Razeghi, E.; Abdollahi, A.; Hashemi-Nazari, S.-S.; Mansournia, M.-A. Potential effects of omega-3 fatty acids on anemia and inflammatory markers in maintenance hemodialysis patients. DARU J. Pharm. Sci. 2014, 22, 11. [CrossRef] [PubMed]
42. Asemi, Z.; Soleimani, A.; Shakeri, H.; Mazroii, N.; Esmaillzadeh, A. Effects of omega-3 fatty acid plus alpha-tocopherol supplementation on malnutrition-inflammation score, biomarkers of inflammation and oxidative stress in chronic hemodialysis patients. Int. Urol. Nephrol. 2016, 48, 1887-1895. [CrossRef] [PubMed]
43. Barden, A.; O’Callaghan, N.; Burke, V.; Mas, E.; Beilin, L.J.; Fenech, M.; Irish, A.B.; Watts, G.F.; Puddey, I.B.; Huang, R.-C.; et al. n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease. Nutrients 2016, 8, 175. [CrossRef] [PubMed]
44. Azizi-Soleiman, F.; Jazayeri, S.; Eghtesadi, S.; Rajab, A.; Heidari, I.; Vafa, M.R.; Gohari, M.R. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. Int. J. Prev. Med. 2013, 4, 922-928. [PubMed]
45. Mocking, R.J.T.; Assies, J.; Bot, M.; Jansen, E.H.J.M.; Schene, A.H.; Pouwer, F. Biological effects of add-on eicosapentaenoic acid supplementation in diabetes mellitus and co-morbid depression: A randomized controlled trial. PLoS ONE 2012, 7, e49431. [CrossRef] [PubMed]
46. Bostock, E.L.; Morse, C.I.; Winwood, K.; McEwan, I.M.; Onambele, G.L. Omega-3 Fatty Acids and Vitamin D in Immobilisation: Part B- Modulation of Muscle Functional, Vascular and Activation Profiles. J. Nutr. Health Aging 2017, 21, 59-66. [CrossRef] [PubMed]
47. Bostock, E.L.; Morse, C.I.; Winwood, K.; McEwan, I.M.; Onambélé-Pearson, G.L. Omega-3 fatty acids and vitamin D in immobilisation: Part A—Modulation of appendicular mass content, composition and structure. J. Nutr. Health Aging 2017, 21, 51-58. [CrossRef] [PubMed]
48. Gerling, C.J.; Whitfield, J.; Mukai, K.; Spriet, L.L. Variable effects of 12 weeks of omega-3 supplementation on resting skeletal muscle metabolism. Appl. Physiol. Nutr. Metab. 2014, 39, 1083-1091. [CrossRef] [PubMed]
49. Krzyminska-Siemaszko, R.; Czepulis, N.; Lewandowicz, M.; Zasadzka, E.; Suwalska, A.; Witowski, J.; Wieczorowska-Tobis, K. The Effect of a 12-Week Omega-3 Supplementation on Body Composition, Muscle Strength and Physical Performance in Elderly Individuals with Decreased Muscle Mass. Int. J. Environ. Res. Public Health 2015, 12, 10558-10574. [CrossRef] [PubMed]
50. Mozaffarian, D.; Rimm, E.B. Fish intake, contaminants, and human health: Evaluating the risks and the benefits. JAMA 2006, 296, 1885-1899. [CrossRef] [PubMed]
51. Sharp, R.P.; Gales, B.J.; Sirajuddin, R. Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol. Am. J. Cardiovasc. Drugs 2017. [CrossRef] [PubMed]
52. Wei, M.Y.; Jacobson, T.A. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: A systematic review and meta-analysis. Curr. Atheroscler. Rep. 2011, 13, 474-483. [CrossRef] [PubMed]
53. Jacobson, T.A.; Glickstein, S.B.; Rowe, J.D.; Soni, P.N. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: A review. J. Clin. Lipidol. 2012, 6, 5-18. [CrossRef] [PubMed]
54. Mori, T.A.; Burke, V.; Puddey, I.B.; Watts, G.F.; O’Neal, D.N.; Best, J.D.; Beilin, L.J. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. Am. J. Clin. Nutr. 2000, 71, 1085-1094. [PubMed]
55. Abbott, K.A.; Burrows, T.L.; Thota, R.N.; Acharya, S.; Garg, M.L. Do omega-3 PUFAs affect insulin resistance in a sex-specific manner? A systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2016, 104, 1470-1484. [CrossRef] [PubMed]
56. Endres, S.; Ghorbani, R.; Kelley, V.E.; Georgilis, K.; Lonnemann, G.; van der Meer, J.W.; Cannon, J.G.; Rogers, T.S.; Klempner, M.S.; Weber, P.C. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N. Engl. J. Med. 1989, 320, 265-271. [CrossRef] [PubMed]
57. Akchurin, O.M.; Kaskel, F. Update on inflammation in chronic kidney disease. Blood Purif. 2015, 39, 84-92. [CrossRef] [PubMed]
58. Yoshino, J.; Smith, G.I.; Kelly, S.C.; Julliand, S.; Reeds, D.N.; Mittendorfer, B. Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults. Physiol. Rep. 2016, 4. [CrossRef] [PubMed]
59. Jankowska, M.; Cobo, G.; Lindholm, B.; Stenvinkel, P. Inflammation and Protein-Energy Wasting in the Uremic Milieu. Contrib. Nephrol. 2017, 191, 58-71. [CrossRef] [PubMed]
60. Rice, H.B.; Bernasconi, A.; Maki, K.C.; Harris, W.S.; von Schacky, C.; Calder, P.C. Conducting omega-3 clinical trials with cardiovascular outcomes: Proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot. Essent. Fatty Acids 2016, 107, 30-42. [CrossRef] [PubMed]
61. Jeromson, S.; Gallagher, I.J.; Galloway, S.D.R.; Hamilton, D.L. Omega-3 Fatty Acids and Skeletal Muscle Health. Mar. Drugs 2015, 13, 6977-7004. [CrossRef] [PubMed]